{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:33:28Z","timestamp":1790674408759,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"vor","delay-in-days":332,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mucosalimmunology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mucosal Immunology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1038\/s41385-020-0334-2","type":"journal-article","created":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T11:06:10Z","timestamp":1597662370000},"page":"523-536","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["A vaccine combination of lipid nanoparticles and a cholera toxin adjuvant derivative greatly improves lung protection against influenza virus infection"],"prefix":"10.1016","volume":"14","author":[{"given":"Valentina","family":"Bernasconi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Norling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inta","family":"Gribonika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li Ching","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Burazerovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagma","family":"Parveen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Sch\u00f6n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneli","family":"Stensson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Bally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6ran","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"H\u00f6\u00f6k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Lycke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1038\/s41385-020-0334-2_bib1","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nri3251","article-title":"Recent progress in mucosal vaccine development: potential and limitations","volume":"12","author":"Lycke","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1038\/s41385-020-0334-2_bib2","doi-asserted-by":"crossref","first-page":"5482087","DOI":"10.1155\/2016\/5482087","article-title":"Mucosal vaccine development based on liposome technology","volume":"2016","author":"Bernasconi","year":"2016","journal-title":"J. Immunol. Res."},{"key":"10.1038\/s41385-020-0334-2_bib3","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3389\/fimmu.2018.00431","article-title":"Lipid-based particles: versatile delivery systems for mucosal vaccination against infection","volume":"9","author":"Corthesy","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1038\/s41385-020-0334-2_bib4","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.3389\/fimmu.2018.02224","article-title":"Nanoparticle vaccines against infectious diseases","volume":"9","author":"Pati","year":"2018","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1038\/s41385-020-0334-2_bib5","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.vaccine.2017.12.001","article-title":"Self-assembling protein nanoparticles with built-in flagellin domains increases protective efficacy of a Plasmodium falciparum based vaccine","volume":"36","author":"Kaba","year":"2018","journal-title":"Vaccine"},{"issue":"1","key":"10.1038\/s41385-020-0334-2_bib6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4049\/jimmunol.1601775","article-title":"Inducing mucosal IgA: a challenge for vaccine adjuvants and delivery systems","volume":"199","author":"Boyaka","year":"2017","journal-title":"J. Immunol."},{"issue":"1","key":"10.1038\/s41385-020-0334-2_bib7","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3390\/vaccines3010148","article-title":"Choice and design of adjuvants for parenteral and mucosal vaccines","volume":"3","author":"Savelkoul","year":"2015","journal-title":"Vaccines"},{"issue":"1","key":"10.1038\/s41385-020-0334-2_bib8","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1080\/21645515.2016.1239668","article-title":"Current prospects and future challenges for nasal vaccine delivery","volume":"13","author":"Yusuf","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"issue":"1","key":"10.1038\/s41385-020-0334-2_bib9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.7774\/cevr.2017.6.1.15","article-title":"The development of mucosal vaccines for both mucosal and systemic immune induction and the roles played by adjuvants","volume":"6","author":"Kim","year":"2017","journal-title":"Clin. Exp. Vaccine Res."},{"issue":"31-32","key":"10.1038\/s41385-020-0334-2_bib10","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.1016\/j.vaccine.2003.10.054","article-title":"Strong local and systemic protective immunity induced in the ferret model by an intranasal virosome-formulated influenza subunit vaccine","volume":"22","author":"Lambkin","year":"2004","journal-title":"Vaccine"},{"key":"10.1038\/s41385-020-0334-2_bib11","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2147\/IJN.S68861","article-title":"Liposomes as nanomedical devices","volume":"10","author":"Bozzuto","year":"2015","journal-title":"Int. J. Nanomed."},{"issue":"6","key":"10.1038\/s41385-020-0334-2_bib12","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/2051013614541440","article-title":"Liposomes as vaccine delivery systems: a review of the recent advances","volume":"2","author":"Schwendener","year":"2014","journal-title":"Ther. Adv. Vaccines"},{"issue":"4","key":"10.1038\/s41385-020-0334-2_bib13","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.4049\/jimmunol.162.4.2432","article-title":"Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity","volume":"162","author":"Agren","year":"1999","journal-title":"J. Immunol."},{"issue":"5","key":"10.1038\/s41385-020-0334-2_bib14","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.4049\/jimmunol.173.5.3310","article-title":"The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues","volume":"173","author":"Eriksson","year":"2004","journal-title":"J. Immunol."},{"key":"10.1038\/s41385-020-0334-2_bib15","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.coph.2018.03.015","article-title":"ADP-ribosylating enterotoxins as vaccine adjuvants","volume":"41","author":"Lycke","year":"2018","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1038\/s41385-020-0334-2_bib16","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.3389\/fimmu.2018.02060","article-title":"Porous nanoparticles with self-adjuvanting M2e-fusion protein and recombinant hemagglutinin provide strong and broadly protective immunity against influenza virus infections","volume":"9","author":"Bernasconi","year":"2018","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1038\/s41385-020-0334-2_bib17","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1046\/j.1440-1711.1998.00750.x","article-title":"A novel concept in mucosal adjuvanticity: the CTA1-DD adjuvant is a B cell-targeted fusion protein that incorporates the enzymatically active cholera toxin A1 subunit","volume":"76","author":"Agren","year":"1998","journal-title":"Immunol. Cell Biol."},{"key":"10.1038\/s41385-020-0334-2_bib18","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/mi.2017.14","article-title":"M2e-tetramer-specific memory CD4 T cells are broadly protective against influenza infection","volume":"11","author":"Eliasson","year":"2017","journal-title":"Mucosal Immunol"},{"issue":"2","key":"10.1038\/s41385-020-0334-2_bib19","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/14760584.2017.1240041","article-title":"M2-based influenza vaccines: recent advances and clinical potential","volume":"16","author":"Kolpe","year":"2017","journal-title":"Expert Rev. Vaccines"},{"issue":"1","key":"10.1038\/s41385-020-0334-2_bib20","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3390\/vaccines3010105","article-title":"M2e-based universal influenza A vaccines","volume":"3","author":"Deng","year":"2015","journal-title":"Vaccines"},{"issue":"9","key":"10.1038\/s41385-020-0334-2_bib21","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.vaccine.2007.12.027","article-title":"CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine","volume":"26","author":"Eliasson","year":"2008","journal-title":"Vaccine"},{"issue":"11","key":"10.1038\/s41385-020-0334-2_bib22","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1073\/pnas.79.11.3604","article-title":"Antigen presentation by Ia+ B cell hybridomas to H-2-restricted T cell hybridomas","volume":"79","author":"Kappler","year":"1982","journal-title":"Proc. Natl Acad. Sci. USA"},{"issue":"6218","key":"10.1038\/s41385-020-0334-2_bib23","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/338765a0","article-title":"A novel MHC class II epitope expressed in thymic medulla but not cortex","volume":"338","author":"Murphy","year":"1989","journal-title":"Nature"},{"key":"10.1038\/s41385-020-0334-2_bib24","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3389\/fimmu.2014.00092","article-title":"Early BCR events and antigen capture, processing, and loading on MHC Class II on B Cells","volume":"5","author":"Avalos","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1038\/s41385-020-0334-2_bib25","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3389\/fimmu.2019.00339","article-title":"CXCR6-deficiency improves the control of pulmonary mycobacterium tuberculosis and influenza infection independent of T-Lymphocyte recruitment to the lungs","volume":"10","author":"Ashhurst","year":"2019","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1038\/s41385-020-0334-2_bib26","first-page":"269","article-title":"Antigenic variation in current human type A influenza viruses: antigenic characteristics of the variants and their geographic distribution","volume":"48","author":"Schild","year":"1973","journal-title":"Bull. World Health Organ."},{"issue":"12","key":"10.1038\/s41385-020-0334-2_bib27","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1084\/jem.20181308","article-title":"CXCR6 regulates localization of tissue-resident memory CD8 T cells to the airways","volume":"216","author":"Wein","year":"2019","journal-title":"J. Exp. Med."},{"issue":"23","key":"10.1038\/s41385-020-0334-2_bib28","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1016\/j.vaccine.2011.03.090","article-title":"A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus","volume":"29","author":"Eliasson","year":"2011","journal-title":"Vaccine"},{"key":"10.1038\/s41385-020-0334-2_bib29","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1021\/acsinfecdis.9b00189","article-title":"Gel Phase 1,2-Distearoyl-sn-glycero-3-phosphocholine-based liposomes are superior to fluid phase liposomes at augmenting both antigen presentation on major histocompatibility complex Class II and costimulatory molecule display by dendritic cells in vitro","volume":"5","author":"Norling","year":"2019","journal-title":"ACS Infect. Dis."},{"issue":"10","key":"10.1038\/s41385-020-0334-2_bib30","doi-asserted-by":"crossref","first-page":"10655","DOI":"10.1021\/nn504210g","article-title":"Brain-penetrating nanoparticles improve paclitaxel efficacy in malignant glioma following local administration","volume":"8","author":"Nance","year":"2014","journal-title":"ACS Nano"},{"key":"10.1038\/s41385-020-0334-2_bib31","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jconrel.2015.11.006","article-title":"PEG modified liposomes containing CRX-601 adjuvant in combination with methylglycol chitosan enhance the murine sublingual immune response to influenza vaccination","volume":"223","author":"Oberoi","year":"2016","journal-title":"J. Control Release"},{"issue":"Pt A","key":"10.1038\/s41385-020-0334-2_bib32","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","article-title":"PEGylation as a strategy for improving nanoparticle-based drug and gene delivery","volume":"99","author":"Suk","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1038\/s41385-020-0334-2_bib33","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.biomaterials.2017.03.007","article-title":"Engineering intravaginal vaccines to overcome mucosal and epithelial barriers","volume":"128","author":"Ji","year":"2017","journal-title":"Biomaterials"},{"issue":"12","key":"10.1038\/s41385-020-0334-2_bib34","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1021\/mp300190g","article-title":"Effect of the poly(ethylene glycol) (PEG) density on the access and uptake of particles by antigen-presenting cells (APCs) after subcutaneous administration","volume":"9","author":"Zhan","year":"2012","journal-title":"Mol. Pharm."},{"issue":"9","key":"10.1038\/s41385-020-0334-2_bib35","doi-asserted-by":"crossref","first-page":"9217","DOI":"10.1021\/acsnano.5b03876","article-title":"Impact of surface polyethylene glycol (PEG) density on biodegradable nanoparticle transport in Mucus ex vivo and distribution in vivo","volume":"9","author":"Xu","year":"2015","journal-title":"ACS Nano"},{"issue":"13","key":"10.1038\/s41385-020-0334-2_bib36","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1016\/j.vaccine.2012.01.070","article-title":"Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens","volume":"30","author":"Watson","year":"2012","journal-title":"Vaccine"},{"key":"10.1038\/s41385-020-0334-2_bib37","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.biomaterials.2017.03.047","article-title":"Vaccine nanocarriers: coupling intracellular pathways and cellular biodistribution to control CD4 vs CD8 T cell responses","volume":"132","author":"Rincon-Restrepo","year":"2017","journal-title":"Biomaterials"},{"key":"10.1038\/s41385-020-0334-2_bib38","doi-asserted-by":"crossref","unstructured":"Schlitzer, A., Zhang, W., Song, M., Ma, X. Recent advances in understanding dendritic cell development, classification, and phenotype. F1000Res. 7, (2018).","DOI":"10.12688\/f1000research.14793.1"},{"key":"10.1038\/s41385-020-0334-2_bib39","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.3389\/fimmu.2018.02409","article-title":"Intestinal CD103(+)CD11b(+) cDC2 conventional dendritic cells are required for primary CD4(+) T and B cell responses to soluble flagellin","volume":"9","author":"Flores-Langarica","year":"2018","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1038\/s41385-020-0334-2_bib40","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1172\/JCI60659","article-title":"Cross-presenting CD103+ dendritic cells are protected from influenza virus infection","volume":"122","author":"Helft","year":"2012","journal-title":"J. Clin. Investig."},{"issue":"2","key":"10.1038\/s41385-020-0334-2_bib41","doi-asserted-by":"crossref","first-page":"259","DOI":"10.4161\/hv.22487","article-title":"New generation of dendritic cell vaccines","volume":"9","author":"Radford","year":"2013","journal-title":"Hum. Vaccine Immunother."},{"issue":"5","key":"10.1038\/s41385-020-0334-2_bib42","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/mi.2014.135","article-title":"Phenotype and function of nasal dendritic cells","volume":"8","author":"Lee","year":"2015","journal-title":"Mucosal Immunol."},{"issue":"10","key":"10.1038\/s41385-020-0334-2_bib43","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/13484","article-title":"A universal influenza A vaccine based on the extracellular domain of the M2 protein","volume":"5","author":"Neirynck","year":"1999","journal-title":"Nat. Med."},{"issue":"1","key":"10.1038\/s41385-020-0334-2_bib44","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.virol.2005.04.004","article-title":"Universal influenza A vaccine: optimization of M2-based constructs","volume":"337","author":"De Filette","year":"2005","journal-title":"Virology"},{"issue":"4","key":"10.1038\/s41385-020-0334-2_bib45","article-title":"An H5N1-based matrix protein 2 ectodomain tetrameric peptide vaccine provides cross-protection against lethal infection with H7N9 influenza virus","volume":"4","author":"Leung","year":"2015","journal-title":"Emerg. Microbes Infect."},{"issue":"9","key":"10.1038\/s41385-020-0334-2_bib46","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.bbagen.2006.05.004","article-title":"Structure-activity relationships of some hederagenin diglycosides: haemolysis, cytotoxicity and apoptosis induction","volume":"1760","author":"Chwalek","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"issue":"4","key":"10.1038\/s41385-020-0334-2_bib47","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1128\/mr.56.4.622-647.1992","article-title":"Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin","volume":"56","author":"Spangler","year":"1992","journal-title":"Microbiol. Rev."}],"container-title":["Mucosal Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41385-020-0334-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41385-020-0334-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933021922001519?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933021922001519?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41385-020-0334-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:07:47Z","timestamp":1761829667000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933021922001519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S1933021922001519"],"URL":"https:\/\/doi.org\/10.1038\/s41385-020-0334-2","relation":{},"ISSN":["1933-0219"],"issn-type":[{"value":"1933-0219","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A vaccine combination of lipid nanoparticles and a cholera toxin adjuvant derivative greatly improves lung protection against influenza virus infection","name":"articletitle","label":"Article Title"},{"value":"Mucosal Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/s41385-020-0334-2","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 \u00a9 Society for Mucosal Immunology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}